NEXTCHEM (MAIRE) AWARDED A FEASIBILITY STUDY BY RÖHM FOR A PMMA-POLYMER CHEMICAL RECYCLING PLANT IN GERMANY BASED ON ITS PROPRIETARY NXRe™ TECHNOLOGY

NEXTCHEM (MAIRE) AWARDED A FEASIBILITY STUDY BY RÖHM FOR A PMMA-POLYMER CHEMICAL RECYCLING PLANT IN GERMANY BASED ON ITS PROPRIETARY NXRe™ TECHNOLOGY

NEXTCHEM will develop a site-specific feasibility study for a chemical plastic recycling plant, fully integrated within Röhm's existing facilities, processing 5,000 tons p.a. of PMMA NEXTCHEM's proprietary NXRe™ technology is able to reduce the...

Datasea Advances Deployment of an Acoustics + AI-Driven Next-Generation Beauty & Health Intelligence System, Addressing a Multi-Billion-Dollar China Market Opportunity

Datasea Advances Deployment of an Acoustics + AI-Driven Next-Generation Beauty & Health Intelligence System, Addressing a Multi-Billion-Dollar China Market Opportunity

BEIJING, Dec. 17, 2025 /PRNewswire/ -- Datasea (Beijing) Technology Co., Ltd. ("Datasea"), a subsidiary of Datasea Inc. (NASDAQ: DTSS), today announced a strategic partnership with Shenzhen Yizhimei Technology Co., Ltd. ("Yizhimei"). Datasea will...

CUHK and MicroSigX partner to launch a breakthrough test aiding early autism diagnosis offering 200 free test quotas

CUHK and MicroSigX partner to launch a breakthrough test aiding early autism diagnosis offering 200 free test quotas

HONG KONG, Dec. 17, 2025 /PRNewswire/ -- The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) announced the official launch of the world's first "AI-Powered Multikingdom Microbial Biomarkers Technology" (MSX Metagenie®)...

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

EFGH and Minerva Sign Strategic MSA to Develop Next-Generation Data Centres in Ghana

EFGH and Minerva Sign Strategic MSA to Develop Next-Generation Data Centres in Ghana

ACCRA, Ghana and SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Embed Financial Group Holdings (EFGH) and Minerva Data Limited, a Hiedberg Holdings company with operations focused on digital infrastructure development in Ghana, have signed a Master...

Samson Food Co Ltd Accelerates Push into the Health Food Market with High-Value Products Combining Hwangto and Fermentation

Samson Food Co Ltd Accelerates Push into the Health Food Market with High-Value Products Combining Hwangto and Fermentation

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Samson Food Co Ltd, an agricultural corporation, is strengthening the added value of traditional foods and positioning itself as a company that supports healthier dietary lifestyles by expanding its...

Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits

Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits

SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio") announced a strategic collaboration agreement. The partnership will focus...

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The...

OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple...

Solace and NetComm Commercialize World's First Wirelessly Powered, Window-Mounted 5G CPE

Solace and NetComm Commercialize World's First Wirelessly Powered, Window-Mounted 5G CPE

MOUNT PEARL, NL and SYDNEY, Dec. 11, 2025 /PRNewswire/ -- Solace Power Inc. ("Solace") and NetComm Wireless ("NetComm") today announced a strategic partnership to co-develop and commercialize the world's first wirelessly powered, window-mounted...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 19
  • menu
    menu